International pharmaceutical companies value the innovative R&D capabilities of Taiwan's biotech industry and academia and are actively exploring teams with a unique potential in Taiwan.
CancerFree Biotech Ltd. is a team dedicated to the analysis of circulating tumor cells (CTCs) and has mastered the core technology of cancer precision medicine. The company's platform is to use patients' CTCs to expand their personalized cancer cells in-vitro, to further screen cancer patients, and to quickly find the right anti-cancer drug for them.
AstraZeneca, a multinational pharmaceutical company, recently joined hands with Taipei Medical University, the National Biotechnology Research Park, the Biomedical Translation Research Center of Academia Sinica, and the Ministry of Science and Technology to host the first International Biomedical Accelerator Collaboration Program.
CancerFree Biotech is the only team dedicated to the analysis of circulating tumor cells (CTCs) and has been selected by the jury for its core technology in cancer precision medicine.